Received Feb 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | — |
conjunctival papillomatosis (CP) treated with 9-valent HPV vaccine/Although human papillomavirus (HPV) vaccine was originally developed for prevention,; Literature Report. This Literature (Spontaneous) report has been received from the authors of a published article, titled as stated above and referred to a 56 -year-old Male patient. The patient's concurrent condition included Conjunctival papillomatosis The patient's past medications were not reported. The patient's concomitant medications were not reported. On an unknown date, patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (dose, route of administration, lot# and expiration date were not reported) for the treatment of Conjunctival papillomatosis. It was reported that although human papillomavirus (HPV) vaccine was originally developed for prevention, it garnered interest for its potential therapeutic role in treating recurrent HPV-associated lesions (Off label use). It was reported that he received one dose of the 9-valent HPV vaccine with no observed regression, followed by a second dose 4 months later. A copy of the published article is attached as further documentation of the patient's experience. This is one of three cases derived from the same literature article (cross-referenced with case# 2386045 and 2378189).
Papilloma conjunctival